SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Herman S, Kronke G, Schett G.Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.Trends Mol Med2008;14:24553.
  • 2
    Maini R, St.Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, for the ATTRACT Study Group.Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial.Lancet1999;354:19329.
  • 3
    Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.Infliximab and methotrexate in the treatment of rheumatoid arthritis.N Engl J Med2000;343:1594602.
  • 4
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al, for the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.Arthritis Rheum2004;50:105165.
  • 5
    St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.Arthritis Rheum2004;50:343243.
  • 6
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al.Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.Arthritis Rheum2003;48:3545.
  • 7
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al.Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).J Rheumatol2003;30:256371.
  • 8
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al.Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial.Ann Intern Med1999;130:47886.
  • 9
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al.A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.N Engl J Med2000;343:158693.
  • 10
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators.Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.Lancet2004;363:67581.
  • 11
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al.Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.Arthritis Rheum1998;41:155263.
  • 12
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators.The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.Arthritis Rheum2006;54:2637.
  • 13
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al.Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.Arthritis Rheum2009;60:227283.
  • 14
    Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al.The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.Arthritis Rheum2011;63:120010.
  • 15
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis Rheum1988;31:31524.
  • 16
    Fries JF, Spitz P, Kraines RG, Holman HR.Measurement of patient outcome in arthritis.Arthritis Rheum1980;23:13745.
  • 17
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al.American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis.Arthritis Rheum1995;38:72735.
  • 18
    Van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al.Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis.Arthritis Rheum1992;35:2634.
  • 19
    Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL.Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria.Arthritis Rheum1996;39:3440.
  • 20
    Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al.Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.Ann Rheum Dis2009;68:95460.
  • 21
    Castrejon I, Ortiz AM, Toledano E, Castaneda S, Garcia-Vadillo A, Patino E, et al.Estimated cutoff points for the 28-joint Disease Activity Score based on C-reactive protein in a longitudinal register of early arthritis.J Rheumatol2010;37:143943.
  • 22
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al.A simplified disease activity index for rheumatoid arthritis for use in clinical practice.Rheumatology (Oxford)2003;42:24457.
  • 23
    Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al.Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.Arthritis Res Ther2005;7:R796806.
  • 24
    Aletaha D, Smolen JS.The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care.Best Pract Res Clin Rheumatol2007;21:66375.
  • 25
    Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al.Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.Arthritis Rheum2008;58:96475.
  • 26
    Guyatt G, Walter S, Norman G.Measuring change over time: assessing the usefulness of evaluative instruments.J Chronic Dis1987;40:1718.
  • 27
    Pye SR, Adams JE, Ward KA, Bunn DK, Symmons DP, O'Neill TW.Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss.Rheumatology (Oxford)2010;49:19438.
  • 28
    Smolen JS, van der Heijde DM, St.Clair EW, Emery P, Bathon JM, Keystone E, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.Arthritis Rheum2006;54:70210.
  • 29
    Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al, for the TEMPO Study Investigators.Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.Arthritis Rheum2006;54:106374.
  • 30
    Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, et al.Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti–tumor necrosis factor antibody, in phase III clinical trials.Arthritis Care Res (Hoboken)2013;65:30913.
  • 31
    Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, et al.Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti–tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.Arthritis Rheum2012;64:206877.